Browse the corpus

Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, represents a significant global health burden. An estimated 10 million individuals experience VTE annually, resulting in over 500,000 fatalities in Europe and a range of 100,000 to 300,000 deaths in the United States. Pulmonary embolism, as the third leading cause of cardiovascular mortality behind heart attack and stroke, presents a complex treatment challenge. While systemic thrombolytic therapy remains part of the pulmonary embolism management arsenal, its effectiveness and safety, particularly for the growing intermediate-risk group, remain debated. Catheter-directed thrombolysis (CDT) has emerged as a potential paradigm shift in the therapeutic landscape of pulmonary embolism. This minimally invasive technique, delivering thrombolytic agents directly to the clot via catheterization, promises targeted therapy with potentially reduced systemic bleeding risks. This activity on CDT for pulmonary embolism is crucial for healthcare professionals involved in pulmonary embolism management. This activity delves into the science and evidence behind CDT, examining its effectiveness, safety, and potential benefits for different patient groups. Participants will gain insights into CDT implementation's technical considerations and possible limitations, identifying knowledge gaps and outlining future research directions. Key endpoints like mortality, hemodynamic improvement, and bleeding risks will be scrutinized within this specific context. By staying informed about the latest advancements and best practices in CDT, healthcare professionals can enhance their knowledge and skills, ultimately improving patient outcomes in managing pulmonary embolism. Objectives: Identify appropriate candidates for catheter-directed thrombolysis in acute pulmonary embolism management based on clinical presentation, risk factors, and imaging findings. Apply evidence-based guidelines and protocols for catheter-directed thrombolysis administration, dosage, and monitoring in managing acute pulmonary embolism. Select appropriate catheterization techniques and thrombolytic agents based on patient characteristics and clot location for catheter-directed thrombolysis.

Identify appropriate candidates for catheter-directed thrombolysis in acute pulmonary embolism management based on clinical presentation, risk factors, and imaging findings. Apply evidence-based guidelines and protocols for catheter-directed thrombolysis administration, dosage, and monitoring in managing acute pulmonary embolism. Select appropriate catheterization techniques and thrombolytic agents based on patient characteristics and clot location for catheter-directed thrombolysis. Collaborate with interventional radiologists and cardiologists to optimize catheter-directed thrombolysis procedures and outcomes in acute pulmonary embolism management. Access free multiple choice questions on this topic.

An estimated 10 million individuals worldwide experience venous thromboembolism annually, leading to over 500,000 fatalities in Europe and a range of 100,000 to 300,000 deaths in the US.[1][2] Pulmonary embolisms can manifest with varying degrees of severity, ranging from asymptomatic to sudden death. This broad spectrum highlights the importance of accurately assessing pulmonary embolism severity from the outset. Given this diversity, it is critical to stratify patients based on their pulmonary embolism-related risk to tailor treatment approaches effectively. While anticoagulation therapy generally suffices for patients at low risk of complications, the benefits of active thrombus removal, such as catheter-directed thrombolysis (CDT), become increasingly evident with the severity of pulmonary embolism.[3] CDT has emerged as a nuanced treatment option, particularly for patients with intermediate to high-risk pulmonary embolism. This intervention aims to reduce the thrombus burden in the pulmonary arteries, potentially improving right ventricular function and patient outcomes[4]. However, the application of CDT is not without risks, as the potential for bleeding and other complications must be weighed against the therapeutic benefits.[5] The landscape of interventional therapies for pulmonary embolism is evolving, with new devices and techniques being developed and approved for clinical use. This dynamic field necessitates a clear understanding of the current state of endovascular interventions and the development of evidence to guide their application in various clinical scenarios.

There are several possible complications from CDT for pulmonary embolism, with most being secondary to the increased risk of bleeding. The risk of major bleeding is significantly lower than with systemic lytic therapy. Systemic lytic therapy for acute pulmonary embolism is associated with a major bleeding risk of up to 20%.[27] In contrast, the risk of bleeding in patients undergoing CDT is 1.4% in intermediate-risk pulmonary embolism and 6.7% in high-risk pulmonary embolism.[28] One of the most common and most feared complications is a hemorrhagic stroke, potentially leading to a devastating outcome for the patient. Other common complications include vascular access-related injuries such as hematoma, pulmonary hemorrhage, retroperitoneal hemorrhage, cardiogenic shock, perforation or dissection of the pulmonary artery, arrhythmias, right-sided valvular regurgitation, pericardial tamponade, and contrast-induced nephropathy.[29]

CDT offers improved clinical outcomes in patients with severe, hemodynamically unstable, massive, or submassive pulmonary embolisms. Without CDT, these patients are at a higher risk of morbidity and mortality. The current guidelines recommend that all healthcare facilities treating pulmonary embolisms establish a PERT.[31] The PERT team is an interprofessional team comprising specialists from various clinical fields, including emergency medicine, critical care, cardiology, internal medicine, radiology, and specialty-trained nurses from critical care, radiology, and emergency care. Clinical pharmacists, especially those trained in critical care, cardiac care, and anticoagulation, are also essential members of this team. Working collaboratively, they can efficiently and effectively deliver CDT to improve patient care. Once CDT is chosen as a management course, the team should counsel the patient and family regarding the procedure's risks and benefits. A trained clinical provider knowledgeable in the risks and benefits should have this discussion with the nurses to ensure informed consent has been obtained. An anesthesiologist or nurse anesthetist should then evaluate the patient to determine the need, mode, and safety of anesthetic delivery. An imaging specialist or structuralist may then be consulted for further recommendations on the size and burden of the pulmonary embolism. The emergency care and critical care nurses must assist in monitoring the patient during the procedure and subsequent infusion therapy for hemodynamic or neurologic complications. The clinical pharmacists assist the interventional team by providing appropriate medication and dosing for the procedure. The critical care pharmacist must help the team adjust other concurrent medications to minimize adverse side effects. Multiple studies have shown that the institution of a PERT can reduce adverse events in pulmonary embolism care [32]. Swift and early diagnosis followed by early treatment is the key to successful pulmonary embolism thrombolysis.

Due to the risk of complications during CDT, close monitoring during thrombolytic infusion is required. Most hospitals require intensive care unit-level monitoring during infusion. The patient should receive neurologic checks every hour and regular vascular access site checks to monitor for early signs of possible complications. It is also recommended that the patient be monitored for 24 to 48 hours after infusion for potential complications in the same manner. If any complications (eg, signs of bleeding or an acute neurologic event) are observed or abnormalities are seen in laboratory data, a clinician should be notified immediately.